Swedish Orphan Biovitrum (STO: SOBI), also known as Sobi, has appointed Duane Barnes as the new head of Sobi in North America.
Mr Barnes will join Sobi in January 2021 and be part of the executive committee.
“Sobi in North America has gone through significant change over the past few years and has exciting launches both underway and coming up in the years ahead,” says Guido Oelkers, chief executive and president of Sobi. “This is why it is such a pleasure to welcome Duane to Sobi. His experience and background will be invaluable as we continue to build our presence in the US and fulfil our commitment to further expand access to patients,” he elaborated
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze